POSTER PRESENTATIONS SESSION II


Poster Session I Poster Session II Poster Session III
  • Health Care Use & Policy
  • Arthritis including skeletal issues

  • Diabetes

  • Endocrine Disorders

  • GI Disorders

  • Hematological Disorders

  • Individual’s Health

  • Respiratory Disorders

  • Skin

 
  • Asthma/Allergy
  • Cardiovascular Disease
  • Eye
  • Neurological
  • Osteoporosis
  • Smoking
  • Urinary/Kidney


 


METHODS & CONCEPTS

PMC1

SIMULATION MODELING OF CARDIOVASCULAR DISEASE: IS APPLYING AVERAGE LIFE EXPECTANCY TO ALL SURVIVORS DETAILED ENOUGH?

 

Proskorovsky I1, Ishak KJ1, Migliaccio-Walle K2, Caro JJ2

 

1Caro Research Institute, Dorval, QC, Canada, 2Caro Research Institute, Concord, MA, USA

PMC2

EFFICIENT DATA MINING AND PROBABILISTIC INFERENCE WITH P-COURSE: A BAYESIAN METHOD WITH MULTILEVEL PRIORS FOR MEDICAL APPLICATIONS

 

Soini EJ1, Martikainen JA2, Lahtinen J3, Myllymäki P3, Kontkanen P3, Valtonen H4, Ryynänen OP5

 

1Department of Health Policy and Management, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 2Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 3Complex Systems Computation Research Group (CoSCo), Helsinki Institute for Information Technology (HIIT), University of Helsinki, Helsinki, Finland, 4Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, 5General Practice, Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland

PMC3

WITHDRAWN

 

PMC4

PRESENTING IGNORANCE: A POSSIBILITY INTERVAL APPROACH TO DEPICT HIGH-LEVEL UNCERTAINTY DUE TO CENSORING OR NON-RESPONDENTS

 

Turunen JH1, Soini EJ2

 

1Equal contribution of both authors. Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 2Department of Social Pharmacy, Department of Health Policy and Management, University of Kuopio, Kuopio, Finland

PMC5

INDIRECT COSTS OF COMMON COLD IN GERMANY

 

Hessel FP, Wasem J

 

University of Duisburg-Essen, Essen, Germany

PMC6

IMPLEMENTING NATURAL HISTORY STUDIES IN EURASIA: THE NIEMANN-PICK EXPERIENCE WITH RAPIDLY CHANGING NATIONAL REGULATIONS

 

Madison M1, Finegan Y1, Sawyer R2, Koval S2, Cox G2

 

1Abt Associates Inc, Lexington, MA, USA, 2Genzyme Corporation, Cambridge, MA, USA

PMC7

Withdrawn

PMC8

ECONOMIC DECISION MODELLING: CALCULATION OF TOTAL NET MONETARY BENEFITS OF GUIDELINE IMPLEMENTATION INTO CLINICAL PRACTICE

 

Hoomans T1, Ament A1, Evers S2, Severens JL3

 

1Maastricht University, Maastricht, The Netherlands, 2Maastricht University, Maastricht, Nepal, 3Academic Hospital Maastricht, Maastricht, The Netherlands

PMC9

A REVIEW OF FACTORS AFFECTING THERAPEUTIC COMPLIANCE

 

Jin J, Li SC

 

National University of Singapore, Singapore, Singapore

PMC10

ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. IS IT WORTHY TO CALCULATE WEIGHT VALUES FOR UTILITY MEASURES?

 

Rebollo P1, Morís J1, Prieto L2, Ortega F3, Ortega T3

 

1BAP Health Outcomes, Oviedo, Spain, 2Madrid, San Agustín de Guadalíx, Madrid, Spain, 3Hospital Universitario Central de Asturias, Oviedo, Spain

PMC11

EFFECTIVE USE OF ELECTRONIC DATA CAPTURE (EDC) TO IMPROVE THE QUALITY AND EFFICIENCY OF THE ANALYSIS OF PATIENT REPORTED OUTCOMES

 

Ooms KL

 

Statwood, HITCHIN, Hertfordshire, UK

PMC12

REVIEW ON THE IMPACT OF DOSE FREQUENCY ON COMPLIANCE AND HEALTH OUTCOMES

 

Shi L1, Hodges M1, Yurgin NR2, Secnik K2

 

1Tulane University, New Orleans, LA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PMC13

EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE QALY GAIN

 

Ohkusa Y, Sugawara T

 

National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan

PMC14

MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS: ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES.

 

Foster JM1, Van der Molen T1, Caeser M2, Hannaford P3

 

1University of Groningen, Groningen, The Netherlands, 2ALTANA Pharma AG, Konstanz, Germany, 3University of Aberdeen, Aberdeen, Scotland, UK

PMC15

HOSPITAL PHARMACY DRUG DELIVERY TIME: A WORK FLOW MANAGEMENT ISSUE

 

Pierce CA1, Baker JJ2, McClard C2

 

1The Resource Group, Richfield, OH, USA, 2The Resource Group, Pickton, TX, USA

PMC16

PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007 PRACTICE EXPENSE CONCEPTUAL METHODOLOGY

 

Pierce CA1, Baker JJ2

 

1The Resource Group, Richfield, OH, USA, 2The Resource Group, Pickton, TX, USA

PMC17

MONITORING OF PHARMACEUTICAL COST OF REIMBURSED MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE DATA WITH COMMERCIAL IMS SALES DATA.

 

Van Wilder P, Arickx F, Van Haeren E, Bormans V

 

RIZIV-INAMI, Brussels, Belgium

PMC18

USING DISTANCE LEARNING TO UNDERSTAND DISCRETE EVENT SIMULATION

 

Hunting B, Moller J, Caro JJ

 

Caro Research Institute, Concord, MA, USA


CANCER

Clinical Outcomes Studies 

PCN1

THE EPIDEMIOLOGIC, HEALTH-RELATED QUALITY OF LIFE, AND ECONOMIC BURDEN OF GASTROINTESTINAL STROMAL TUMORS

 

Reddy P1, Boci K2, Charbonneau C3, Pashos CL1

 

1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc, Bethesda, MD, USA, 3Pfizer, New York, NY, USA

PCN2

INCIDENCE AND SURVIVAL STUDY BY STAGE AND ESTIMATED PREVALENCE OF RENAL PARENCHYMA CANCER IN FRANCE

 

Danzon A1, Langlois C1, Grosclaude P2, Colonna M3, Delafosse P3, Martin E4, Molinié F5, Tretarre B6, Velten M7, Levrat F8

 

1Registre des tumeurs du Doubs, Besançon, France, 2Tarn Cancer registry, Albi, France, 3Isere cancer registry, Meylan, France, 4Somme cancer registry, Amiens, France, 5Loire Atlantique and Vandée cancer redistry, Nantes, France, 6Herault cancer registry, Montpelliers, France, 7Universite Louis Pasteur, strasbourg, France, 8Pfizer, Paris, France

PCN3

EPIDEMIOLOGIC, HUMANISTIC AND ECONOMIC BURDEN OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

 

Banks J1, Gupta K1, Balu S1, Chen E2, Komatsuzaki Y2, Charbonneau C3, Pashos CL1

 

1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc, Bethesda, MD, USA, 3Pfizer, New York, NY, USA

Cost Studies

PCN4

A COMPARATIVE BUDGET IMPACT (BI) ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) 500µG Q3W VERSUS OTHER ERYTHROPOIESIS STIMULATING PROTEINS (ESP) IN CHEMOTHERAPY-INDUCED ANEMIA (CIA) IN SPAIN

 

Pérez Alcántara F1, Badia X2, Arocho R3

 

1Health Outcomes Research, Barcelona, Barcelona, Spain, 2Health Outcomes Research Europe, Barcelona, Spain, 3Amgen SA, Barcelona, Barcelona, Spain

PCN5

HEXVIX FLUORESCENCE CYSTOSCOPY FOR SUPERFICIAL BLADDER CANCER DIAGNOSIS: ANALYSIS OF BUDGET IMPACT ON THE SWEDISH HEALTH SERVICE

 

Thompson G1, Durrant H2, Kloster Y3

 

1Bridgehead International Ltd, Melton Mowbray, Leicestershire, UK, 2Bridgehead International Limited, Melton Mowbray, Leicestershire, UK, 3Photocure ASA, Oslo, Norway

PCN6

PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM IS COST-SAVING COMPARED WITH FILGRASTIM FOR BREAST CANCER IN SPAIN

 

Mayordomo JI1, Lopez Pousa A2, Arocho R3, Doan QV4, Dubois R4, Liu Z4

 

1Hospital Clinico Lozano Blesa, Zaragoza, Spain, 2Hospital Sant Pau, Barcelona, Spain, 3Amgen SA, Barcelona, Spain, 4Cerner Health Insights, Beverly Hills, CA, USA

PCN7

IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF CHEMOTHERAPY OF ADVANCED OVARIAN CANCER

PCN8

RISE OF HEALTH RESOURCE UTILIZATION AND COSTS FOR SEQUENTIAL DOCETAXEL IN NODE-POSITIVE PRIMARY BREAST CANCER IN GERMAN HOSPITALS

 

Ihbe-Heffinger A1, Wagenpfeil S1, Jacobs VR1, Gillessen P1, Bernard R1, Sattler D2, Kuhn W3

 

1Klinikum rechts der Isar der Technischen Universität München, München, Germany, 2Städtisches Krankehaus München-Harlaching, München, Germany, 3Universität Bonn, Bonn, Germany

PCN9

ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY – A COST-SAVING SECOND-LINE TREATMENT OPTION?

 

Gabriel A, Pirk O, Kotowa W

 

Fricke & Pirk GmbH - Member of the IMS Health Group, Nuremberg, Germany

PCN10

INCREMENTAL COST-EFFECTIVENESS RATIO OF DARBEPOETIN ALFA (ARANESP®) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER PATIENTS

 

Borget I1, Tilleul P2, Joly AC2, Chouaid C2

 

1Saint-Antoine Hospital, Paris, France, France, 2Saint-Antoine Hospital, Paris, France

PCN11

PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTHCARE PERSPECTIVE

 

Côté I1, Leighl NB2, Gyldmark M3, Maturi B1

 

1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2Princess Margaret Hospital, Toronto, ON, Canada, 3F Hoffmann La Roche, Basel, Switzerland

PCN12

COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

 

Orlewska E1, Szczesna A2, Gyldmark M3, Szkultecka-Debek M4

 

1Centrum Farmakoekonomiki, Warsaw, Poland, 2Regional Lung Diseases Hospital, Otwock, Poland, 3F Hoffmann La Roche, Basel, Switzerland, 4Roche Polska Sp. z o.o, Warsaw, Poland

PCN13

COST-EFFECTIVENESS OF ADJUVANT CAPECITABINE, MAYO CLINIC AND DE GRAMONT REGIMENS FOR STAGE III COLON CANCER IN THE FRENCH SETTING

 

Tilleul P1, Perrocheau G2, Lafuma A3, Roux E4

 

1Saint-Antoine Hospital, Paris, France, 2Centre Renée Gauducheau, Saint Herblain, France, 3Cemka-Eval, Bourg-la-Reine, France, 4Roche, Neuilly sur Seine, France

PCN14

COST-EFFECTIVENESS STUDY OF AN ASPIRIN CHEMOPREVENTION ASSOCIATED OR NOT WITH A COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER

 

Francesconi C1, Benamouzig R2, Launois R1

 

1REES, Paris, France, 2Hopital Avicenne, Bobigny, France

PCN15

CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES´ C COLON CANCER: PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL - DATA FROM CZECH PERSPECTIVE

 

Jiraskova L1, Dolezal T2

 

1Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic, 2Charles University, Prague, Czech Republic

PCN16

COST-EFFECTIVENESS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA IN SPAIN

 

Maroto P1, Villavicencio H2, Piñol C3, Urruticoechea L4

 

1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Fundació Puigvert, Barcelona, Spain, 3Q.F. Bayer, S.A, Barcelona, Spain, 4Q. F. Bayer, S.A, Barcelona, Spain

PCN17

COST EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM OR FILGRASTIM IN THE MEDICAL TREATMENT OF BREAST CANCER IN ITALY

 

Chiroli S1, Dubois RW2, Doan QV2, Liu Z2, Heissel A3, Palmeri S4, Danova M5

 

1Amgen, Milan, Italy, 2Cerner Health Insights, Beverly Hills, CA, USA, 3Amgen Europe, Zug, Switzerland, 4Policlinico Universitario P. Giaccone, Palermo, Italy, 5Clinica Medica, Pavia, Italy

PCN18

A SENSITIVITY ANALYSIS OF THE COST PER QUALITY ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC)

 

Geary U1, Lewis G2, Erny S3, Gyldmark M4, Morlotti L5, Walzer S6

 

1Roche Products Limited, Hertfordshire, UK, 2Roche Products Limited, Welwyn Garden City, Herts, UK, 3F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5Analytica Int, Loerrach, Germany, 6Analytica International, Loerrach, Germany

PCN19

COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN SPAIN.

 

Brosa M1, Robinson P2, Brown B2

 

1Oblikue Consulting, Barcelona, SC, Spain, 2IMS Health, London, UK

PCN20

COST-EFFECTIVENESS ANALYSIS OF LETROZOLE COMPARED TO TAMOXIFEN FOR TREATMENT OF EARLY BREAST CANCER IN THE HUNGARIAN HEALTH CARE SETTING

 

Kosa J

 

Novartis Hungary Ltd, Budapest, Pest, Hungary

PCN21

RETROSPECTIVE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF VARIOUS TREATMENT SCHEMES IN PATIENTS WITH ADVANCED HODGKIN'S DISEASE

 

Tolkushin AG1, Yagudina RI1, Moiseeva TN2, Khabriev RU1

 

1Moscow Medical Academy, Moscow, Russia, 2Hematological Scientific Center of the Russian Academy of Medical Sciences, Moscow, Russia

PCN22

COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN.

 

Brosa M1, Arocho R2

 

1Oblikue Consulting, Barcelona, SC, Spain, 2Amgen SA, Barcelona, Spain

PCN23

ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)

 

Hieke K1, Herold M2

 

1NEOS Health, Binningen, Switzerland, 2HELIOS Klinikum Erfurt, Erfurt, Germany

PCN24

PEGFILGRASTIM PRIMARY PROPHYLAXIS IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN FRANCE

 

Bogillot O1, Dubois R2, Doan QV2, Liu Z2, Heissel A3, Di Palma M4

 

1Amgen S.A, Paris, France, 2Cerner Health Insights, Beverly Hills, CA, USA, 3Amgen Europe, Zug, Switzerland, 4Insitut Gustave Roussy, Villejuif Cedex, France

PCN25

TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE: A COST OF ILLNESS AND MODEL VALIDATION STUDY

 

Caekelbergh K, Annemans L

 

IMS Health Economics and Outcomes Research (HEOR), Brussels, Belgium

PCN26

PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS

 

Rubio Terres C1, Alvarez Sanz C2, Marlene Gylmark GM3

 

1Hero Consulting, Madrid, Spain, 2Roche Farma, Madrid, Spain, 3Hoffman-La Roche Inc, Basel, Switzerland

PCN27

COST-EFFECTIVENESS AND COST-UTILITY OF FENTANYL TTS (DUROGESIC® 25, 50) VS. SR/IR ORAL MORPHINES IN THE MANAGEMENT OF CHRONIC CANCER PAIN

 

Estevez-Carrizo FE

 

University of Montevideo, Uruguay, Montevideo, Uruguay

PCN28

SHOULD FOTEMUSTINE BE USED AS THE FIRST LINE TREATMENT

 

Faluta T, Czech M, Pachocki R

 

Servier Polska, Warsaw, Poland

PCN29

ECONOMIC ADVANTAGES AND TIMESAVING OF USING OXALIPLATIN CONCENTRATED SOLUTION VERSUS OXALIPLATIN LYOPHILISED POWDER FOR INFUSION

 

Favier B1, Spath HM2, Anhoury P3, Pacull A3

 

1Centre Leon Berard, Lyon, France, 2GRESAC, Lyon, France, 3IMS Health Consulting & Services, Puteaux, France

PCN30

ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS

 

Tilleul P1, Jasso Mosqueda G2, Trancart A2, Joly AC1, Tournigand C1, Maindrault-Goebel F1, Le Pen C2, De Gramont A1

 

1Saint-Antoine Hospital, Paris, France, 2Aremis-aegisnet, Neuilly sur Seine, France

PCN31

A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER IN POLAND

 

Skowron A, Polak S, Brandys J

 

Jagiellonian University, Cracow, Malopolska, Poland

PCN32

COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL

 

Araujo G1, Fonseca M1, Bigni R2

 

1Axia.Bio Consulting, São Paulo, Brazil, 2INCA, Rio de Janeiro, Brazil

PCN33

A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): A RETROSPECTIVE STUDY

 

Van Bellinghen LA1, Demarteau N1, Annemans L1, Bracco A2

 

1IMS HEOR, Brussels, Belgium, 2Amgen (Europe) GmbH, Zug, Switzerland

PCN34

EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS. FURTHER EVIDENCE FROM THE HABIT STUDY.

 

Negrini C1, Falcone A2

 

1Pbe consulting, Milano, Italy, 2AstraZeneca, Basiglio, MI, Italy

PCN35

BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN

 

Maroto P1, Villavicencio H2, Piñol C3, Urruticoechea L4

 

1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Fundació Puigvert, Barcelona, Spain, 3Q.F. Bayer, S.A, Barcelona, Spain, 4Q. F. Bayer, S.A, Barcelona, Spain

PCN36

BURDEN OF CERVICAL CANCER IN POLAND.

 

Kawalec P1, Glogowski C2, Krzyzanowska A3

 

1Centrum HTA, Krakow, Poland, 2GSK Commercial Sp. z o.o, Warsaw, Poland, 3GlaxoSmithKline Poland, Warsaw, Poland

PCN37

COMPARING MANAGEMENT PATTERNS AND ASSOCIATED COSTS FOR WOMEN WITH ABNORMAL CERVICAL CYTOLOGY IN 5 DIFFERENT COUNTRIES

 

Rash B1, Van Kriekinge G2

 

1Health Market International, Ann Arbor, MI, USA, 2GlaxoSmithKline Biologicals, Rixensart, Brabant, Belgium

PCN38

'COST OF ILLNESS' ANALYSIS OF RENAL CELL CARCINOMA

 

Lang K1, Danchenko N1, Gondek K2, Schwartz B2, Thompson D1

 

1i3 Innovus, Medford, MA, USA, 2Bayer Pharmaceuticals Corporation, West Haven, CT, USA

PCN39

COST-UTILITY ANALYSIS IN A FRENCH SETTING OF ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

 

Fagnani F1, Colin X1, Arveux P2, Coudray-Omnès C3

 

1Cemka-Eval, BOURG-LA-REINE, France, 2CLCC Georges-François Leclerc, Dijon, France, 3Roche, Neuilly sur Seine, France

PCN40

COST EFFECTIVENESS OF RITUXIMAB PLUS CVP IN PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA

 

Maturi B1, Tong W2, Gyldmark M3, Creeden J3, Aultman R3, Jost F3

 

1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland

PCN41

COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING

 

Fonseca M1, Araujo G1, Saad E2, Uehara R3

 

1Axia.Bio Consulting, São Paulo, Brazil, 2Dendrix, São Paulo, Brazil, 3Sanofi Aventis, São Paulo, Brazil

PCN42

COST EFFECTIVENESS OF FULVESTRANT AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE RESPONSIVE ADVANCED BREAST CANCER

 

Hirsch M1, Gait C2, Chambers J2

 

1AstraZeneca UK Ltd, Macclesfield, Cheshire, UK, 2Mapi Values Ltd, Macclesfield, Cheshire, UK

PCN43

COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE

 

Brown B1, Robinson P1, Launois R2, Griebsch I3

 

1IMS Health, London, UK, 2REES, Paris, France, 3Merck KGaA, Darmstadt, Germany

PCN44

COST UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR BREAST CANCER IN THE UK

 

Booth P1, Dubois R2, Doan QV2, Liu Z2

 

1Amgen Ltd, Cambridge, UK, 2Cerner Health Insights, Beverly Hills, CA, USA

PCN45

COST EFFECTIVENESS OF ADDING IMATINIB TO CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): AN EXPLORATORY ANALYSIS FOR THE UK

 

Botteman MF, Tran KT, Stephens JM

 

PharMerit North America LLC, Bethesda, MD, USA

PCN46

EPOIETIN ALPHA TREATMENT FOR CANCER PATIENTS WITH CHEMOTHERAPY INDUCED ANAEMIA - A COST-EFFECTIVENESS ANALYSIS FOR SWEDEN

 

Borg S, Glenngård AH, Persson U

 

The Swedish Institute for Health Economics, IHE, Lund, Sweden

Health Care Use & Policy Studies

PCN47

COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

 

Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Betlehem J3, Ember I3

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PCN48

A MODEL FOR PROJECTING BOWEL CANCER INCIDENCE AND MORTALITY: APPLICATION TO THE UK BOWEL CANCER SCREENING PROGRAM.

 

Muston D1, Howard PA1, Lee DW2

 

1Heron Evidence Development Ltd, Letchworth, Herts, UK, 2GE Healthcare, Waukesha, WI, USA

PCN49

FACTORS INFLUENCING INEQUITABLE ACCESS TO RADIATION THERAPY: THE CASE STUDY OF CANCER PATIENTS IN THAILAND

 

Prakongsai P1, Chunharas S2, Tangcharoensathien V1

 

1International Health Policy Program - Thailand, Nonthaburi, Thailand, 2National Health Foundation, Bangkok, Thailand

PCN50

BOWEL CANCER SCREENING. BALANCING COST-EFFECTIVENESS AND AFFORDABILITY.

 

Howard PA1, Muston D1, Lee DW2

 

1Heron Evidence Development Ltd, Letchworth, Herts, UK, 2GE Healthcare, Waukesha, WI, USA

PCN51

PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS: ANALYSIS OF US OUTPATIENT DATA 1996-2004

 

Balkrishnan R, Bhosle MJ

 

The Ohio State University College of Pharmacy, Columbus, OH, USA

PCN52

SCREENING RATE IN THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

 

Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Betlehem J3, Ember I3

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PCN53

AGE-GROUP SPECIFIC COVERAGE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

 

Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Betlehem J3, Ember I3

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 3University of Pécs, Pécs, Hungary

Methods & Concepts

PCN54

ESTIMATING THE CLINICAL BENEFITS OF HPV-16/18 VACCINATION: CHALLENGES OF MODELING PREDICTED CASES OF CERVICAL CANCER IN POLAND AND MEXICO, TWO COUNTRIES WITH DIFFERING DEGREES OF CERVICAL DISEASE AND POPULATION STABILITY

 

Rogoza RM1, Standaert B2

 

1i3 Innovus, Burlington, Ontario, Canada, 2GlaxoSmithKline Biologicals, Rixensart, Belgium

PCN55

LONG TERM CLINICAL EFFECT OF AN HPV-VACCINE FOR THE PREVENTION OF CERVICAL CANCER IN FRANCE IN RELATION TO AGE OF VACCINATION: RESULTS FROM A MARKOV MODEL.

 

Demarteau N1, Detournay B2, El Hasnaoui A3, Standaert B4, Annemans L5

 

1IMS HEOR, Brussels, Belgium, 2CEMKA-EVAL, Bourg-la-Reine, France, 3GlaxoSmithKline France, Marly-Le-Roi Cedex, France, 4GlaxoSmithKline Biologicals, Rixensart, Belgium, 5Health Economics and Outcomes Research, Brussels, Belgium

PCN56

OUTCOME VALIDATION OF A SUCCINCT HPV INFECTION MODEL FOR FRANCE

 

Demarteau N1, Detournay B2, El Hasnaoui A3, Standaert B4, Annemans L5

 

1IMS HEOR, Brussels, Belgium, 2CEMKA-EVAL, Bourg-la-Reine, France, 3GlaxoSmithKline France, Marly-Le-Roi Cedex, France, 4GlaxoSmithKline Biologicals, Rixensart, Belgium, 5Health Economics and Outcomes Research, Brussels, Belgium

PCN57

TRASTUZUMAB USE FOR METASTATIC BREAST CANCER- IS "MEDIAN TIME TO TREATMENT FAILURE" AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?

 

Hammerman A, Klang SH, Liebermann N

 

Clalit Health Services, Tel-Aviv, Israel

PCN58

PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER PATIENTS: SURVEY RESPONSES COMPARED TO AN ADMINISTRATIVE REGISTER

 

Booth N1, Rissanen P1, Tammela T2

 

1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland

PCN59

THE ECONOMIC VALUE OF INNOVATIVE TREATMENTS OVER THE PRODUCT LIFE CYCLE: THE CASE OF TRASTUZUMAB

 

Garrison LP, Veenstra DL

 

University of Washington, Seattle, WA, USA

PCN60

ASSESSMENT OF THE COMPUTATIONAL INTELLIGENCE BASED MODELS USEFULNESS FOR PHARMACOECONOMICS NEEDS

 

Polak S1, Skowron A2, Mendyk A1, Brandys J1

 

1Jagiellonian University, Cracow, Malopolska, Poland, 2Jagiellonian University, Cracow, Poland

PCN61

Withdrawn

   

PCN62

UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

 

Wild D1, Walker M2, Pettengell R3, Lewis G4

 

1Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 2Roche Products Ltd, Welwyn Garden City, Herts, UK, 3St Georges Hospital, London, UK, 4Roche Products Limited, Welwyn Garden City, UK

PCN63

ADVANCED CUTANEOUS MALIGNANT MELANOMA: SYSTEMATIC REVIEW OF PHARMACOECONOMIC AND QUALITY OF LIFE STUDIES

 

Machado M1, Cashin R2, Lui P3, Hemels M4, Corey-Lisle P5, Einarson TR2

 

1Universidad de Chile, Santiago, RM, Chile, 2University of Toronto, Toronto, ON, Canada, 3University of Toronto, M5S 2S2, ON, Canada, 4Bristol-Myers Squibb, Braine-L'Alleud, Belgium, 5Bristol-Myers Squibb, Wallingford, CT, USA

PCN64

DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS

 

Brodersen J1, Thorsen H2

 

1University of Copenhagen, Copenhagen, Denmark, 2Copenhagen University, Copenhagen, Denmark

PCN65

Withdrawn

 

 

PCN66

ADHERENCE IN CANCER PATIENTS RECEIVING ORAL CAPECITABINE

 

Roth S1, Simons S1, Arjukese A1, Braun M1, Ko Y2, Kuhn W1, Mey U1, Schwindt P3, Wolter H3, Jaehde U1

 

1University of Bonn, Bonn, NRW, Germany, 2Johanniter Hospital, Bonn, NRW, Germany, 3Oncology Practice, Bonn, NRW, Germany

PCN67

PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING WITH 5HT3 RECEPTOR ANTAGONISTS AND HEALTH RELATED QOL

 

García Pulgar MS1, Constenla M2, Montaño A3, García Dominguez R4, Pérez Manga G5, Batista N6, Ordóñez A7, Montalar J8, Benavides M9, Ruíz MA10, Garrido J10, Alvarez Sanz C1

 

1Roche Farma S.A, Madrid, Spain, 2Complejo Hospitalario Provincial de Pontevedra, Pontevedra, Spain, 3Complejo Hospitalario Juan Ramón Jiménez, Huelva, Spain, 4Hospital Universitario de Salamanca, Salamanca, Spain, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Hospital Universitario de Canarias, La Laguna, Spain, 7Hospital Universitario La Paz, Madrid, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Complejo Hospitalario Carlos Haya, Málaga, Spain, 10Universidad Autónoma de Madrid, Madrid, Spain

PCN68

QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN

 

Fukuda T1, Shimozuma K2, Ohsumi S3, Mukai H4, Morita S5, Imai H6, Watanabe T7, Ohashi Y1

 

1The University of Tokyo, Bunkyo, Tokyo, Japan, 2University of Marketing and Distribution Sciences / Public Health Research Foundation, Kobe, Hyogo, Japan, 3Shikoku Cancer Center, Matsuyama, Ehime, Japan, 4National Cancer Center, Kashiwa, Chiba, Japan, 5Kyoto University, Kyoto, Kyoto, Japan, 6National Institute of Public Health, Wako, Saitama, Japan, 7Hamamatsu Oncology Center, Hamamatsu, Shizuoka, Japan

PCN69

HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY

 

Nafees B1, Stafford MR1, Bhalla S2, Watkins J3

 

1UBC, London, UK, 2Lilly UK, Bassingstoke, UK, 3Lilly UK, Basingstoke, UK

PCN70

RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS

 

Horsman JR1, Spitzer R2, Hsu T1, Duckworth J3, Barr RD1, Furlong W1

 

1McMaster University, Hamilton, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3McMaster Children's Hospital, Hamilton, ON, Canada

PCN71

PSYCHOMETRIC EVALUATION OF A PATIENT REPORTED OUTCOME QUESTIONNAIRE FOR METASTATIC COLORECTAL CANCER

 

Colwell HH1, Pritchard ML1, Mathias SD1, Lu ZJ2, Wright N3

 

1Ovation Research Group, San Francisco, CA, USA, 2Amgen, Inc, Thousand Oaks, CA, USA, 3Amgen, Inc, Cambridge, England

PCN72

A COMPARISON OF PATIENT REPORTED OUTCOMES ACROSS CURATIVE TREATMENTS OF ELDERLY PROSTATE CANCER PATIENTS

 

Jayadevappa R, Chhatre S, Wein AJ, Malkowicz SB

 

University of Pennsylvania, Philadelphia, PA, USA

PCN73

VARIATIONS IN SATISFACTION WITH CARE AND EMOTIONAL WELL-BEING OF EARLY-STAGE PROSTATE CANCER PATIENTS

 

Jayadevappa R1, Chhatre S1, Wein AJ2, Malkowicz SB1

 

1University of Pennsylvania, Philadelphia, PA, USA, 2University of Pennsylvania, Phildelphia, PA, USA

PCN74

UTILITIES ASSOCIATED WITH NON-SMALL CELL LUNG CANCER (NSCLC): A COMMUNITY STUDY

 

Tabberer M1, Stamuli E1, Walker M2, Summerhayes M2, Lees M1

 

1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Roche Products Ltd, Welwyn Garden City, Herts, UK


INFECTION

Cost Studies

PIN1

CLINICAL AND ECONOMIC IMPACT OF INTRODUCING A QUADRIVALENT (6, 11, 16, 18) HUMAN PAPILLOMAVIRUS VACCINE IN SWITZERLAND

 

Gerber S1, Heinzl S2, Largeron N3, Bénard S4

 

1CHUV, Lausanne, Switzerland, 2Kantonsspital, Bruderholz, Switzerland, 3sanofi pasteur MSD, Lyon, France, 4st[è]ve consultants, Lyon, France

PIN2

A COST-BENEFIT ANALYSIS OF DIFFERENT VARICELLA VACCINATION STRATEGIES INVOLVING ITALIAN CHILDREN AND ADOLESCENTS

 

Marocco A1, Bamfi F1, Banz K2, Boccalini S3, Bechini A3, Bonanni P3

 

1GlaxoSmithKline Spa, Verona, Veneto, Italy, 2Outcomes International, Basel, Switzerland, 3University of Florence, Florence, Italy

PIN3

COST – EFFECTIVNESS ANALYSIS OF TONSILOPHARYNGITIS AND RHYNOPHARINGITIS ACCUTA, ANTIBIOTIC TREATMANT, SRBIJA, NIS REGION

 

Mihajlovic MM1, Nikolic S2

 

1City Pharmacy Nis, Nis, Yugoslavia, 2Government Primary Health Care Institution, Nis, Serbia, Serbia and Montenegro

PIN4

ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE INTENSIVE CARE UNIT: A COST-EFFECTIVENESS ANALYSIS

 

Kulikov A, Krysanov I, Lomakin A

 

Moscow Medical Academy, Moscow, Russia

PIN5

THE COST EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

 

Kowalik E1, Niewada M2, Jakubczyk M3, Horban A4, Berak H4, Szkultecka-Debek M5

 

1Institute of Cardiology, Warsaw, Poland, 2Medical University of Warsaw, Warsaw, Poland, 3Warsaw School of Economics, Warsaw, Poland, 4Regional Hospital of Infectious Diseases, Warsaw, Poland, 5Roche Polska Sp. z o.o, Warsaw, Poland

PIN6

PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN GERMANY

 

Goertz A1, Dubois R2, Doan QV2, Liu Z2, Heissel A3, Von Minckwitz G4

 

1Amgen Germany GmbH, Munich, Germany, 2Cerner Health Insights, Beverly Hills, CA, USA, 3Amgen Europe, Zug, Switzerland, 4Universitäts-Frauenklinik Frankfurt, Frankfurt, Germany

PIN7

Withdrawn

PIN8

COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA

 

van Hulst M1, Dhingra-Kumar N2, Van der Schaaf IP3, Smit Sibinga CT4, Postma MJ5

 

1Groningen University Institute for Drug Exploration / Martini Hospital, Groningen, The Netherlands Antilles, 2WHO, Geneva, Switzerland, 3VU, Amsterdam, The Netherlands, 4Sanquin Consulting Services, Groningen, The Netherlands, 5University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, Groningen, The Netherlands

PIN9

COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) AND RIBAVIRIN ( COPEGUS) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND HUMAN IMMUNODEFICIENCY VIRUS ( HIV) CO-INFECTION

 

Rubio Terres C1, Alvarez Sanz C2, Patel K3

 

1Hero Consulting, Madrid, Madrid, Spain, 2Roche Farma, Madrid, Spain, 3Hoffman-La Roche Inc, Nutley, NJ, USA

PIN10

COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN ITALY

 

Eandi M1, Iannazzo S2, Pradelli L2, Patel K3, Giuliani G4

 

1Università di Torino, Turin, Italy, 2Advanced Research Srl, Turin, Italy, 3Hoffmann-La Roche Inc, Nutley, NJ, USA, 4Roche S.p.A, Milano, Italy

PIN11

COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN FINLAND

 

Järvinen A1, Joutseno J2, Gyldmark M3

 

1Helsinki University Hospital, Helsinki, Finland, 2Roche Oy, Espoo, Finland, 3F Hoffmann La Roche, Basel, Switzerland

PIN12

COST MINIMALISATION ANALYSIS OF AVERAGE ACUTE HOSPITAL INFECTIONS TREATMENT WITH TARGOCID (TEICOPLANIN) OR VANCOMYCINE FROM SERVICE-PROVIDER PERSPECTIVE IN POLAND

 

Kawalec P1, Lis J2

 

1Centrum HTA, Krakow, Poland, 2Sanofi-Aventis, Warsaw, Poland

PIN13

ECONOMIC EVALUATION OF EARLY MONOTHERAPY WITH INTERFERON VERSUS DELAYED COMBINATION THERAPY WITH INTERFERON AND RIBAVIRIN IN PATIENTS WITH ACUTE HEPATITIS C

 

Dintsios CM1, Haverkamp A2, Krauth C2

 

1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 2Hannover Medical School, Hannover, Germany

PIN14

ECONOMIC EVALUATION OF CASPOFUNGIN (CANCIDAS®) VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL THERAPY OF SUSPECTED SYSTEMIC FUNGAL INFECTION IN THE GERMAN HOSPITAL SETTING

 

Kaskel P1, Tuschy S2, Wagner A1, Bannert C3, Cornely OA4, Glasmacher A2, Lütkes P5, Lipp HP6, Ullmann AJ7

 

1MSD Sharp & Dohme GmbH, Haar, Germany, 2Bonn University Hospital, Bonn, Germany, 3Augsburg Academic Hospital, Augsburg, Germany, 4Cologne University Hospital, Köln, Germany, 5Essen University Hospital, Essen, Germany, 6Tubingen University and University Hospital, Tübingen, Germany, 7Johannes Gutenberg-University Mainz, Mainz, Germany

PIN15

CHRONIC HEPATITIS B (CHB) MANAGEMENT COSTS IN SWEDEN

 

De Cock E1, Dale P1, Cerri KH2, Zammit D2, Flamholc L3

 

1United Biosource, London, England, UK, 2Bristol-Myers Squibb, Braine l'Alleud, Wallonie, Belgium, 3Dept of Infectious Diseases, Malmo, Sweden

PIN16

AN OBSERVATIONAL HEALTH-ECONOMIC ANALYSIS OF THE TREATMENT OF PATIENTS WITH VORICONAZOLE IN A REAL LIFE SETTING

 

Van Campenhout H1, De Mees V1, Marbaix S1, Annemans L2

 

1Pfizer, Brussels, Belgium, 2Health Economics and Outcomes Research, Brussels, Belgium

PIN17

THE COST-EFFECTIVENESS OF A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN GERMANY

 

Carroll SM1, Scott DA1, Sidhu MK1, Runge C2

 

1Fourth Hurdle Consulting, London, UK, 2Wyeth Pharma GmbH, Muenster, Germany

PIN18

COST-UTILITY ANALYSIS OF TREATMENT ALTERNATIVES IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B

 

Sun X1, Li Y2, Zhao L3

 

1Department of Clinical Epidemiology and Evidence-based Medicine, West China Hospital, Sichuan University, Chengdu, China, 2West China Hospital, Sichuan University, Chengdu, China, 3Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

PIN19

COST-EFFECTIVENESS OF MASS VACCINATION WITH A ROTAVIRUS VACCINE IN THE NETHERLANDS

 

Al MJ1, Goossens L1, Hövels AM2, Michielsen CP2, Standaert BA3

 

1Erasmus MC, Rotterdam, The Netherlands, 2GlaxoSmithKline The Netherlands, Zeist, The Netherlands, 3GlaxoSmithKline Biologicals, Rixensart, Belgium

PIN20

COSTS AND OUTCOMES OF NOSOCOMIAL PNEUMONIA IN A SAMPLE OF BELGIAN HOSPITALS

 

Spaepen E1, Merchant S2, Neslusan C2, Annemans L3

 

1IMS Health, Brussels, BRUSSELS, Belgium, 2Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 3Health Economics and Outcomes Research, Brussels, Belgium

Health Care Use & Policy Studies

PIN21

COST-BENEFIT ANALYSIS OF VACCINATION PROGRAMME AGAINST POLIOMYELITIS IN MALAYSIA: ORAL POLIO VACCINE (OPV) VS INACTIVATED POLIO VACCINE (IPV)

 

Aljunid S

 

National University of Malaysia, Kuala Lumpur, Malaysia

PIN22

TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH MULTIDRUG RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS (MRSA) IN CANADIAN TEACHING HOSPITALS: INTERIM ANALYSIS

 

Iskedjian M1, Machado M2, Costei A1, Vicente C3, Han D3, Einarson TR2, Piwko C1

 

1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Wyeth Pharmaceuticals, Markham, ON, Canada

PIN23

INDICATOR OF ANTIBIOTIC USE IN PUBLIC PHARMACY CHAIN BELGRADE

 

Sovtic DD1, Tasic L2, Stojanovic S1

 

1Pharmacy Institution Belgrade, Belgrade, Serbia and Montenegro, 2Faculty of pharmacy, University of Belgrade, Belgrade, Serbia and Montenegro

PIN24

THE USE OF ANTIBIOTICS IN CHILDREN POPULATION IN BELGRADE REGION

 

Sovtic DD1, Tasic L2, Stojanovic S1

 

1Pharmacy Institution Belgrade, Belgrade, Serbia and Montenegro, 2University of Belgrade, Belgrade, Serbia and Montenegro

PIN25

LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS

 

Van Hulst M1, Dekens KG2, Vogels WHM3, Postma MJ4, Visser T2

 

1Martini Hospital / GUIDE, Groningen, The Netherlands, 2Martini Hospital, Groningen, The Netherlands, 3Martini Hospital / Laboratory for Infectious Diseases, Groningen, The Netherlands, 4University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, Groningen, The Netherlands

PIN26

Withdrawn

   

PIN27

ECONOMIC MODELLING TO DETERMINE THE COST-EFFECTIVENESS OF TREATMENT OF PATIENTS WITH HISTOLOGICALLY MILD CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA-2B PLUS RIBAVIRIN

 

Campbell S1, Norris S1, Mernagh P1, Batey R2, Dore GJ3

 

1Health Technology Analysts Pty Ltd, Balmain, NSW, Australia, 2Drug and Alcohol Clinical Services, Hunter New England Area Health Service, Wallsend, NSW, Australia, 3Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst, NSW, Australia

PIN28

IS THE PRESCRIBING OF ANTIBIOTICS FOR THE MOST COMMON INFECTIONS IN PRIMARY HEALTH CARE RATIONAL OR NOT?

 

Duborija-Kovacevic N1, Glomazic Z2, Goranovic S3, Tomic Z4

 

1University of Montenegro Medical School, Podgorica, Serbia and Montenegro, 2The Republic Health Insurance Fund of Montenegro, Podgorica, Serbia and Montenegro, 3Medical School of the University of Montenegro, Podgorica, Serbia and Montenegro, 4Medical School of the University in Novi Sad, Novi Sad, Serbia and Montenegro

Methods & Concepts

PIN29

Withdrawn

 

 

PIN30

PSYCHOMETRIC VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA) QUESTIONNAIRE IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS.

 

Wild D1, Reaney MD1, Donatti C1, Keating K2

 

1Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 2Bayer HealthCare Pharmaceuticals, West Haven, CT, USA

Patient Reported Outcomes

PIN31

HEALTH RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B PATIENTS

 

Li SC1, Ong SC2, Lim SG3

 

1National University of Singapore, Singapore, Singapore, 2National University of Singapore, Singapore, Singapore, Singapore, 3National University of Singapore, National University Hospital, Singapore, Singapore, Singapore

PIN32

VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE

 

Fumaz C1, Knobel H2, Segador A3, Lorenzo A4, González J4, García Pulgar M5, Badia X6, Perulero N6

 

1Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 2Hospital del Mar, Barcelona, Spain, 3Hospital Reina Sofía, Córdoba, Spain, 4Hospital La Paz, Madrid, Spain, 5Roche Farma, Madrid, Spain, 6Health Outcomes Research Europe, Barcelona, Spain


MENTAL HEALTH

Clinical Outcomes Studies

PMH1

COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): IMPACT OF COEXISTING CONDITIONS

 

Schlander M1, Schwarz O1, Foster EM2, Hakkaart-van Roijen L3, Jensen PS4, Persson U5, Santosh PJ6, Trott GE7, MTA Cooperative Group O8

 

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University of North Carolina, Chapel Hill, NC, USA, 3Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands, 4Columbia University, New York, NY, USA, 5The Swedish Institute for Health conomics, IHE, Lund, Sweden, 6Institute of Child Health - Great Ormond Street Hospital, London, UK, 7University of Wuerzburg, Aschaffenburg, Germany, 8National Institutes of Mental Health, Bethesda, MD, USA

PMH2

PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER: A CROSS- SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION IN SPAIN

 

Sicras A1, Rejas J2, Navarro R1, Serrat J1, Blanca M1

 

1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain

PMH3

PREVALENCE AND COMORBIDITY BURDEN IN PATIENTS WITH BIPOLAR DISORDERS: CROSS-SECTIONAL ANALYSIS OF A HEALTH -PROVIDER ADMINISTRATIVE CLAIM DATABASE

 

Sicras A1, Rejas J2, Navarro R1, Serrat J1, Blanca M1

 

1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain

PMH4

ASSOCIATION BETWEEN CHANGES ON THE NEGATIVE SYMPTOM ASSESSMENT SCALE AND MEASUREES OF FUNCTIONAL OUTCOME IN SCHIZOPHRENIA

 

Leeuwenkamp O1, Velligan D2, Wang M2, Haig G3, Lancaster S3, Taylor T4, Alphs L3

 

1Organon International, Molenstraat, Oss, The Netherlands, 2University of Texas, San Antonio, TX, USA, 3Pfizer Inc, Ann Arbor, MI, USA, 4Pfizer, Ann Arbor, MI, USA

PMH5

A 3-MONTH ASSESSMENT OF TREATMENT PRESCRIBED TO PATIENTS WITH ADHD AND ITS IMPACT ON CLINICAL SEVERITY AND QOL OUTCOMES ACROSS 10 EUROPEAN COUNTRIES. RESULTS FROM ATTENTION DEFICIT/ HYPERACTIVITY DISODER OBSERVATIONAL RESEARCH IN EUROPE (ADORE)

 

Mata Lorenzo MJ1 , Poole L1, Spiel G2, Dalsgaard S3, Falissard B4, Le Heuzey MF5, Rothenberger A6, Dopfner M7, Baldursson G8, Curatolo P9, Pereira RR10, Vlasveld L11, Nøvik T12, Hervas A13, Preuss U14, Steinhausen HC15, Rasmussen P16, Coghill D17, Riley AW18, 19Forrest CB

 

1Eli Lilly & Company Limited, Windlesham, United Kingdom, 2Landeskrankenhaus Klagenfurt, Klagenfurt, Austria, 3Psykiatric Hospital for Children and Adoloscents, Risskov, Denmark, 4Hôpital Paul Brousse, Paris, France, 5Hopital Robert Debré, Paris, France, 6Georg-August-Universität Göttingen, Göttingen, Germany, 7Klilnik und Poliklinik fur Psychiatrie und Psychotherapie, Köln, Germany, Landspitali University Hospital8, Reykjavik, Iceland, 9Clinica Sant’Alessandro, Rome, Italy, 10Medisch Centrum Rijnmond-Zuid, Rotterdam, The Netherlands, 11Reinier de Graaf Gasthuis, Delft, The Netherlands, 12BUPA-Poliklinisk enhet, Drammen, Norway, 13CAP Rambla, Barcelona, Spain, 14Kinder-u. Jugendpsych.Poliklinik, Bern, Switzerland, 15FMH Kinder-u.Jugendpsychiatrie, Zurich, Switzerland, 16BNK, Göteborg, Sweden, 17Centre for Child Health, Dundee, UK, 18Baltimore, USA, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

PMH6

MENTAL HEALTH IN THE FIRST MONTHS OF HEMODIALYSIS AS A PREDICTOR OF SURVIVAL

 

Valdés C1, García Mendoza M1, Rebollo P2, Ortega F1

 

1Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 2BAP Health Outcomes, Oviedo, Asturias, Spain

Cost Studies 

PMH7

OFF-LABEL UTILIZATION OF METHYLPHENIDATE FOR ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY: INSIGHTS FROM THE NORDBADEN PROJECT

 

Schlander M1, Schwarz O1, Viapiano M2, Bonauer N2

 

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany

PMH8

BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN

 

Darba J1, Restovic G1, Rejas J2

 

1Universitat de Barcelona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain

PMH9

COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN FIVE JURISDICTIONS

 

Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Persson U4, Santosh PJ5, Trott GE6, MTA Cooperative Group O7

 

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands, 3Columbia University, New York, NY, USA, 4The Swedish Institute for Health conomics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg, Aschaffenburg, Germany, 7National Institutes of Mental Health, Bethesda, MD, USA

PMH10

FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON THE NIMH MTA STUDY

 

Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Persson U4, Santosh PJ5, Trott GE6, MTA Cooperative Group O7

 

1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands, 3Columbia University, New York, NY, USA, 4The Swedish Institute for Health conomics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg, Aschaffenburg, Germany, 7National Institutes of Mental Health, Bethesda, MD, USA

PMH11

RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA

 

Gagnon M1, Rive B2, Hux M3, Cochran J2, Guilhaume C2

 

1McMaster University, Hamilton, ON, Canada, 2Lundbeck SAS, Paris, France, 3Innovus Research Inc, Burlington, ON, Canada

PMH12

PHARMACOECONOMIC ANALYSIS OF ANTIDEPRESSANTS IN BRAZIL

 

Machado M1, Iskedjian M2, Ruiz I1, Einarson TR3

 

1Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, RM, Chile, 2PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 3University of Toronto, Toronto, ON, Canada

PMH13

COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

 

Fantino B1, Moore N2

 

1ADIM-AGORAS, Lyon, France, 2Victor Segalen University, Bordeaux Cedex, France

PMH14

PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA: THE HUNGARIAN EXPERIENCE

 

Hansen K1, Bitter I2, Launois R3, Sapin C4

 

1H. Lundbeck A/S, Paris, France, 2Semmelweis University, Budapest, Hungary, 3REES, Paris, France, 4Lundbeck SAS, Paris, France

PMH15

COST-EFFECTIVENESS OF AMISULPRID COMPARED TO RISPERIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND

 

Kowalik E1, Jakubczyk M2, Lis J3, Niewada M4

 

1Institute of Cardiology, Warsaw, Poland, 2Warsaw School of Economics, Warsaw, Poland, 3Sanofi-Aventis, Warsaw, Poland, 4Medical University of Warsaw, Warsaw, Poland

PMH16

COST EFFECTIVENESS MODEL COMPARING FAST DISSOLVING OLANZAPINE AND CONVENTIONAL OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA

 

Ozsogut B1, Saylan M2

 

1Yeditepe University Faculty of Pharmacy, Istanbul, Turkey, 2Eli Lilly and Company, Istanbul, Turkey

PMH17

COST-EFFECTIVENESS OF LONG ACTING METHYLPHENIDATE-OROS IN ADHD YOUTHS WITH SUBOPTIMAL SYMPTOM CONTROL ON IMMEDIATE-RELEASE METHYLPHENIDATE IN THE NETHERLANDS

 

Faber A1, Van Agthoven M2, Kalverdijk L3, Tobi H1, De Jong-van den Berg L1, Annemans L4, Postma M1

 

1University of Groningen, Groningen, The Netherlands, 2Janssen-Cilag BV, Tilburg, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands, 4Health Economics and Outcomes Research, Brussels, Belgium

PMH18

DIRECT COST OF DEPRESSION – ANALYSIS OF A GERMAN CLAIMS DATABASE

 

Gothe H1, Volmer T2, Höer A1, Mangiapane S1, Runge C2, Glaeske G3, Häussler B1

 

1IGES GmbH, Berlin, Germany, 2Wyeth Pharma GmbH, Münster, Germany, 3ZeS, Centre of Social Policy Research, Faculty 11: Human and Health Sciences, University of Bremen, Germany, Bremen, Germany

PMH19

IMPACT OF REMISSION IN MAJOR DEPRESSIVE DISORDER ON ECONOMIC BURDEN OF ILLNESS IN SWEDEN

 

Sobocki P1, Ekman M1, Ågren H2, Runeson B2, Jönsson B3

 

1Stockholm Health Economics, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Stockholm School of Economics, Stockholm, Sweden

PMH20

TREATMENT PATHWAYS AND COST ASSESSMENT OF SCHIZOPHRENIA IN GREECE: A PRIMARY ANALYSIS

 

Aggelopoulos E1, Geitona M2, Zaharakis K3, Kakavas P4, Karpouza V5, Kesidou S6, Kousoulakou C7, Bilanakis N8, Ollandezos M9, Papamichael E10, Papanicolaou S11, Chaidemenos A12, Chamogeorgakis T13, Kyriopoulos J9

 

1Eginitio Hospital, University of Athens, Athens, Greece, 2University of Thessaly, Volos, Greece, 3Ygeia Hospital, Athens, Greece, 4Sinouri Hospital, Athens, Greece, 5Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece, 6Social Insurance Institute, Athens, Greece, 7Institute foe Economic and Industrial Research, Athens, Greece, 8University Hospital of Ioannina, Ioannina, Greece, 9National School of Public Health, Athens, Greece, 10General Public Hospital Nikea, Piraeus, Greece, 11Janssen-Cilag Pharmaceutical SACI, Athens, Greece, 12Psychiatric Hospital of Attica, Athens, Greece, 13Psychiatric Hospital of Athens, Dromokaitio, Athens, Greece

PMH21

COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER

 

Malone DC

 

University of Arizona, Tucson, AZ, USA

PMH22

REHOSPITALIZATION RATES IN SCHIZOPHRENIA: COMPREHENSIVE LITERATURE REVIEW

 

Rabinowitz J1, Ingham M2, Caleo S3, Levine SZ1

 

1Bar Ilan University, Ramat Gan, Israel, 2Johnson & Johnson, Raritan, NJ, USA, 3Janssen Pharmaceutica N.V, Beerse, Belgium

Health Care Use & Policy Studies

PMH23

PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING – NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE

 

Soini EJ1, Rissanen T1, Tiihonen J2, Hodgins S3, Eronen M4, Ryynänen OP5

 

1University of Kuopio, Canthia, Kuopio, Finland, 2University of Kuopio, Niuvanniemi Hospital, Kuopio, Finland, 3Institute of Psychiatry, London, UK, 4Vanha Vaasa Hospital, Vaasa, Finland, 5University of Kuopio, Kuopio, Finland

PMH24

ASSESSMENT OF RESOURCE UTILISATION IN ADULTS DIAGNOSED WITH DEPRESSION IN THE UK: A GPRD-BASED STUDY

 

Bineau S, Saragoussi D, Despiegel N, Toumi M, Milea D, Verpillat P

 

H. Lundbeck A/S, Paris, France

PMH25

Withdrawn

 

PMH26

RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA IN 5 EUROPEAN COUNTRIES

 

Leeuwenkamp O1, Perry R2, Morlock R3, Jones E2, Taylor T4

 

1Organon International, Molenstraat, Oss, The Netherlands, 2Adelphi Group Products, Bollington, Cheshire, UK, 3Pfizer Inc, New York, NY, USA, 4Pfizer, Ann Arbor, MI, USA

PMH27

COST-EFFECTIVENESS OF COGNITIVE-BEHAVIOURAL THERAPY (CBT) FOR MENTAL ILLNESS: AN INTERNATIONAL REVIEW

 

Payne K1, Myhr G2

 

1Caro Research Institute, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada

PMH28

THE MANAGEMENT OF SCHIZOPHRENIA THROUGH CLINICAL PATHWAYS

 

Panella M1, Demarchi ML2, Carnevale L2, Castignoli G2, Valsesia R2, Vanetti M2

 

1University of Eastern Piedmont, Novara, Italy, 2Local Health Authority 13 of Novara, Novara, Italy

PMH29

ACUTE HOSPITALIZATION IN THE ELDERLY:RELATIONSHIP WITH PSYCHIATRIC MORBIDITY AND SOCIAL EQUITY IN HEALTH CARE ACESS IN SINGAPORE

 

Ng TP1, Feng L2, Chiam PC3, Kua EH1

 

1National University of Singapore, Singapore, Singapore, 2National Universtiy of Singapore, Singapore, Singapore, 3Institute of Mental Health, Singapore, Singapore

PMH30

DIFFUSION OF NEWLY-APPROVED GENERIC DRUG PRODUCT USE WITHIN A STATE EMPLOYEE PRESCRIPTION DRUG PROGRAM: A COMPARISON OF MAIL ORDER VERSUS RETAIL PHARMACY CLAIMS

 

Johnsrud M

 

The University of Texas at Austin, Austin, TX, USA

PMH31

PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA

 

Gothe H1, Höer A1, Seidlitz C1, Wittrup-Jensen KU2, Glaeske G3

 

1IGES GmbH; pharmafacts GmbH, Berlin, Germany, 2Janssen-Cilag GmbH, Neuss, Germany, 3ZeS, Centre of Social Policy Research, Faculty 11: Human and Health Sciences, University of Bremen, Germany, Bremen, Germany

PMH32

ANALYSIS OF A MULTINATIONAL, CROSS-SECTIONAL SURVEY OF PHYSICIAN DESCRIPTIONS AND PERCEPTIONS OF PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

 

Leeuwenkamp O1, Perry R2, Milligan G2, Morlock R3, Lecrubier Y4

 

1Organon International, Molenstraat, Oss, The Netherlands, 2Adelphi Group Products, Bollington, Cheshire, UK, 3Pfizer Inc, New York, NY, USA, 4Hôpital Pitié Salpêtrière, Paris, France

Methods & Concepts

PMH33

STRUCTURAL EQUATION MODELLING OF SCHIZOPHRENIA EARLY RETIREMENT IN GERMANY

 

Clouth J1, Eichmann F2, Davidov E3

 

1Lilly Germany, Bad Homburg, Germany, 2Kendle, Munich, Germany, 3Justus Liebig Universitaet Giessen, Giessen, Germany

PMH34

IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN SCHIZOPHRENIC PATIENTS SWITCHED TO RISPERIDONE LONG-ACTING INJECTION (RLAI):

 

Peuskens J1, Povey M2, Diels J3, Van der Veken J4, Jacobs A5

 

1Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 2SGS Biopharma, Wavre, Belgium, 3Janssen Pharmaceutica, beerse, Belgium, 4Janssen Cilag, Berchem, Belgium, 5Janssen Pharmaceutica, Beerse, Belgium

PMH35

REDUCTION IN SUICIDAL IDEATION AND VIOLENT BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR)

 

Hustig H1, Peuskens J2, Olivares J3, Povey M4, Jacobs A5

 

1Glenside Hospital, Fullarton, South Australia, Australia, 2Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 3Servicio de Psiquiatria Hospital, Vigo, Spain, 4SGS Biopharma, Wavre, Belgium, 5Janssen Pharmaceutica, Beerse, Belgium

PMH36

6-MONTH FOLLOW-UP FROM THE ELECTRONIC- SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR) OF PATIENTS IN SPAIN WHO WERE INITIATED TO RISPERIDONE LONG-ACTING INJECTION (RLAI).

 

Olivares J1, Rodriguez A2, Povey M3, Diels J4, Jacobs A5

 

1Servicio de Psiquiatria Hospital, Vigo, Spain, 2Janssen cilag, Madrid, Spain, 3SGS Biopharma, Wavre, Belgium, 4Janssen Pharmaceutica N.V, Beerse, Belgium, 5Janssen Pharmaceutica, Beerse, Belgium

PMH37

BURDEN OF ILLNESS OF PATIENTS WITH ANXIETY IN THE UK

 

Makinson G, Koncz T, Lister S

 

Pfizer Limited, Tadworth, Surrey, UK

PMH38

A MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW TREATMENTS FOR DEPRESSION

 

Sobocki P1, Ekman M1, Ågren H2, Jönsson B3

 

1Stockholm Health Economics, Stockholm, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Stockholm, Sweden, 3Stockholm School of Economics, Stockholm, Stockholm, Sweden

PMH39

USE OF VERBALLY ADMINISTERED AND VERBALLY ORIENTING SCALES TO IMPROVE DATA COLLECTION.

 

Wood A1, Wenzel KW2

 

1ClinPhone, Nottingham, UK, 2ClinPhone, Oregon, WI, USA

PMH40

ASSESSING SELECTION BIAS ON TREATMENT EFFECTS IN OBSERVATIONAL STUDIES WITH REPEATED OUTCOME MEASURES: REGRESSION, PROPENSITY SCORING, FIXED-EFFECTS MODELS, AND BAYESIAN ESTIMATION METHODS

 

Ratcliffe M

 

Eli Lilly and Company Limited, Windlesham, Surrey, UK

Patient Reported Outcomes

PMH41

ANXIETY DISORDERS: THE PATIENTS' PERSPECTIVE

 

Wade AG1, Jorgensen TR2, Sapin C2, Le Lay A2, François C2

 

1CPS Research, Glasgow, UK, 2Lundbeck SAS, Paris, France

PMH42

QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES

 

Leeuwenkamp O1, Perry R2, Morlock R3, Jones E2, Taylor T4

 

1Organon International Inc, Molenstraat, Oss, The Netherlands, 2Adelphi Group Products, Bollington, Cheshire, UK, 3Pfizer Inc, New York, NY, USA, 4Pfizer, Ann Arbor, MI, USA

PMH43

IMPACT OF NEGATIVE SYMPTOMS ON FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES

 

Leeuwenkamp O1, Perry R2, Morlock R3, Jones E2, Taylor T4

 

1Organon International, Molenstraat, Oss, The Netherlands, 2Adelphi Group Products, Bollington, Cheshire, UK, 3Pfizer Inc, New York, NY, USA, 4Pfizer, Ann Arbor, MI, USA

PMH44

TRAJECTORIES OF PATIENT AND CLINICIAN REPORTED ANTIPSYCHOTIC COMPLIANCE IN THE SOHO STUDY AND THEIR CAUSES AND CONSEQUENCES

 

Croudace TJ1, Shi L2, Novick D3, Montgomery W4, Brown J3

 

1University of Cambridge, Cambridge, UK, 2Tulane University, New Orleans, LA, USA, 3Eli Lilly and Company Limited, Windlesham, Surrey, UK, 4Eli Lilly and Company, Sydney, NSW, Australia

PMH45

CROSS-SECTIONAL EVALUATION OF HEALTH STATE UTILITY IN SWEDISH OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

 

Eriksson T

 

Department of Psychiatry, Linköping, Sweden

PMH46

ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D)

 

Meads DM, McKenna SP, Doward LC

 

Galen Research, Manchester, UK

PMH47

MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE ABUSE TREATMENT: A PROPORTIONAL HAZARD APPROACH

 

Ciesla JR, Valle M, Spear SF

 

Northern Illinois University, DeKalb, IL, USA


OBESITY

Clinical Outcomes Studies

POB1

ASSESSMENT OF THE CLINICAL RISK FACTORS FOR METABOLIC SYNDROME IN A NATIONAL PRIMARY CARE ELECTRONIC HEALTH RECORD (EHR) DATABASE

 

Brixner D1, Said Q1, Oderda GM2

 

1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2University of Utah, Salt Lake City, UT, USA

Cost Studies

POB2

COST-EFFECTIVENESS OF TREATING CARDIOMETABOLIC PATIENTS WITH RIMONABANT (ACOMPLIA®) IN A DANISH SETTING

 

Knudsen MS1, Poulsen PB2, Serup-Hansen N3

 

1Muusmann Research & Consulting AS, Copenhagen, Denmark, 2Muusmann Research & Consulting AS, Kolding, Denmark, 3Sanofi-aventis, Hoersholm, Denmark

POB3

BURDEN OF ILLNESS OF ABDOMINAL OBESITY: A RETROSPECTIVE CHART REVIEW

 

Strens D1, Lamotte M2, Fassotte C3, Annemans L1

 

1IMS Health, Brussels, Belgium, 2IMS Health, Brussel, Brabant, Belgium, 3sanofi-aventis, Diegem, Brabant, Belgium

Methods & Concepts

POB4

USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK

 

Mangiapane S1, Gothe H1, Schiffhorst G1, Aidelsburger P2, Fuchs SM2, Wasem J3, Glaeske G4, Häussler B1

 

1IGES GmbH, Berlin, Germany, 2Carem GmbH, Sauerlach, Germany, 3University of Duisburg-Essen, Essen, Germany, 4ZeS, Centre of Social Policy Research, Faculty 11: Human and Health Sciences, University of Bremen, Germany, Bremen, Germany

POB5

A MODELLED COST-EFFECTIVENESS EVALUATION OF SIBUTRAMINE THERAPY IN A HIGH RISK OBESE POPULATION

 

Walters N1, Makino K1, Hutchinson J1, Shorter N2, Swanson M2, Schulz M2

 

1M-TAG, a unit of IMS, Chatswood, NSW, Australia, 2Abbott Australasia, Botany, NSW, Australia

POB6

IN EUROPE, HOW REPRESENTATIVE ARE OVERWEIGHT/OBESE SUBJECTS RECRUITED VIA THE INTERNET?

 

Zhou X1, Radigue C2, Allshouse AA3, Gilsenan A1

 

1RTI Health Solutions, Raleigh, NC, USA, 2Sanofi Synthelabo Recherche, Paris, France, 3RTI Health Solutions, North Carolina, NC, USA

Patient Reported Outcomes

POB7

THE RELATIONSHIP BETWEEN WEIGHT CHANGES AND RELATED CHANGES IN HEALTH-RELATED UTILITY: EVIDENCE OF CAUSE AND AFFECT

 

Woehl A, Currie CJ

 

Cardiff University, Cardiff, UK

POB8

THE IMPACT OF BODY WEIGHT ON UTILITY SCORES IN PATIENTS WITH TYPE 2 DIABETES

 

Dennett SL1, Secnik K2, Yurgin NR2, McDonald-Everett CM2

 

1Strategic Health Outcomes, Carmel, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

POB9

DEVELOPMENT OF A NEW QUESTIONNAIRE FOR IDENTIFING PREDICTIVE FACTORS INFLUENCING WEIGHT LOSS THERAPIES

 

Ruíz MA1, Costa M1, Rubio MA2, Iruarrizaga I3, Almendro C4, Moreno B5, Salvador J6, Antón J7, Bande C8, García Pulgar MS9

 

1Universidad Autónoma de Madrid, Madrid, Spain, 2Hospital Clínico Universitario San Carlos, Madrid, Spain, 3Universidad Complutense de Madrid, Madrid, Spain, 4Centro de Salud Torrent, Valencia, Spain, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Clínica Universitaria de Navarra, Pamplona/Iruña, Spain, 7CAP Manso, Barcelona, Spain, 8Complejo Hospitalario Cristal-Piñor, Orense, Spain, 9Roche Farma S.A, Madrid, Spain

POB10

RIMONABANT IMPROVES HEALTH-RELATED QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES: RIO-DIABETES STUDY

 

Kolotkin RL1, Crosby RD2, Scheen A3

 

1Duke University Medical Center, Durham, NC, USA, 2Neuropsychiatric Research Institute, Fargo, ND, USA, 3University of Liège, Liège, Belgium


PAIN

Clinical Outcomes Studies

PPN1

INTRAVENOUS PARACETAMOL IN POSTOPERATIVE PAIN MANAGEMENT – SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

 

Golicki D, Niewada M

 

Medical University of Warsaw, Warsaw, Poland

PPN2

META-ANALYSIS OF DULOXETINE VS. PREGABALIN AND GABAPENTIN IN THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHIC PAIN

 

Quilici S1, Chancellor J1, Lothgren M2, Simon D3, Said G4, Le TK5, Garcia-Cebrian A6, Monz B7, Kajdasz D5

 

1i3 Innovus, Uxbridge, Middlesex, UK, 2i3 Innovus (Employed by Innovus at the time the research was performed), Uxbridge, Middlesex, UK, 3La Pitié-Salpêtrière Hospital, Paris, France, 4Hôpital de Bicêtre, Le Kremlin-Bicêtre, France, 5Eli Lilly, Indianapolis, IN, USA, 6Eli Lilly and Company Limited, Basingstoke, UK, 7Boehringer Ingelheim GmbH, Ingelheim, Germany

PPN3

SAFETY OF METAMIZOLE, KETOPROFEN AND PARACETAMOL – ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING

 

Golicki D1, Niewada M1, Grygier K2, Scibiorski C2

 

1Medical University of Warsaw, Warsaw, Poland, 2Bristol-Myers Squibb, Warsaw, Poland

Cost Studies

PPN4

ECONOMIC EVALUATION COMPARING BMP-2 (INDUCTOSTM) VERSUS CURRENT TREATMENT IN CHRONIC LOWER BACK PAIN IN THE SPANISH SETTING

 

Serrano D1, Rodríguez J2, Lizan L3, Poyatos J4, Chhabra A5

 

1Medtronic Iberica S.A, Madrid, Spain, 2Medtronic Iberia, Madrid, Madrid, Spain, 3Universidad Jaume I, Castelló de la Plana, Spain, 4Hospital General de Castellón, Castellón de la Plana, Spain, 5Medtronic Europe SA, Tolochenaz, Switzerland


STROKE

Cost Studies

PST1

BUDGETARY IMPACT ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE: A US HEALTH PLAN PERSPECTIVE

 

Earnshaw SR1, Wilson MR1, Joshi AV2

 

1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk, Inc, Princeton, NJ, USA

PST2

STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND PRELIMINARY GERMAN RESULTS

 

Payne K1, Caro JJ2, Proskorovsky I1, Lordan N2, Huybrechts KF2, Ishak KJ1, Rylander A3, Kolominsky-Rabas P4

 

1Caro Research Institute, Montreal, QC, Canada, 2Caro Research Institute, Concord, MA, USA, 3AstraZeneca R&D Sodertalje, Sodertalje, Sweden, 4Interdisciplinary Center for Public Health Studies. University of Erlangen-Nuremberg, Erlangen, Germany

PST3

RESOURCE UTILIZATION AND COSTS OF STROKES IN A THIRD LEVEL HOSPITAL IN MéXICO

 

Carbajal A1, Soto H2, Salazar J3, Zanela O4, Talavera J5

 

1Hospital de Especialidades, IMSS, Delegacion Cuauhtemoc, Mexico D.F, Mexico, 2Universidad del Estado de Mexico, Toluca, Edo de Mexico, Mexico, 3Hospital de Especialidades, IMSS, Delegación Cuauhtemoc, Mexico D.F, Mexico, 4Universidad del Estado De México, Toluca, Estado de Mexico, Mexico, 5Hospital de especialidades, IMSS, Delegacion Cuauhtemoc, México D.F, Mexico

PST4

DIFFERENCES IN DISCHARGE LOCATION FOR PATIENTS WITH MULTIPLE ISCHEMIC STROKE ADMISSIONS: IMPLICATIONS FOR POST-ACUTE CARE COSTS

 

O'Brien JA, Duran PA, Caro JJ

 

Caro Research Institute, Concord, MA, USA

Health Care Use & Policy Studies

PST5

THE WEAKNESS OF TEAMWORK BETWEEN NURSES AND PHYSIOTHERAPISTS IN CARING FOR STROKE PATIENTS IN HUNGARY

 

Betlehem J1, Horváth M1, Boncz I2, Sebestyén A2

 

1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration (OEP), Budapest, Hungary

Patient Reported Outcomes

PST6

UTILITY LOSS AND INDIRECT COSTS AFTER STROKE IN SWEDEN

 

Lindgren P1, Glader EL2, Jönsson B3

 

1Stockholm Health Economics, Stockholm, Sweden, 2Umeå Universitet, Umeå, Sweden, 3Stockholm School of Economics, Stockholm, Sweden


SURGERY

Cost Studies

PSU1

A COST-EFFECTIVENESS EVALUATION OF VACUUM ASSISTED CLOSURE (V.A.C. THERAPY) TREATMENT FOR DEHISCED CHEST WOUND PATIENTS

 

Song D1, Miller E2, Keith MS3

 

1University of Chicago, Chicago, IL, USA, 2KCI, San Antonio, TX, USA, 3KCI USA, Inc, San Antonio, TX, USA

PSU2

ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY: PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

 

Soini EJ1, Keränen J2, Ryynänen OP3, Keränen U4

 

1Department of Social Pharmacy, Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, 2Faculty of Medicine, University of Kuopio, Kuopio, Finland, 3Department of Public Health and General Practice, University of Kuopio, Kuopio, Finland, 4Hospital District of Helsinki and Uusimaa, Department of Operative Specialties, Hyvinkää Hospital Region, Hyvinkää, Finland

PSU3

DEMOGRAPHIC PREDICTORS OF RESOURCE UTILIZATION AND COSTS OF SOLID ORGAN TRANSPLANTATION IN BRITISH COLUMBIA, CANADA.

 

Levy AR, Sobolev B2, James D3, Sullivan SD4, Partovi N5, Barrable W55, Levy R5

 

1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3St Paul's Hospital, Vancouver, BC, Canada, 4University of Washington, Seattle, WA, USA, 5BC Transplant Society, Vancouver, BC, Canada

Cost Studies

PSU4

VENTRAL, UMBILICAL, AND INGUINAL HERNIA: REVIEW OF THE CURRENT LITERATURE

 

De Jonge P1, Llyod A1, Tan R2, Narewska J1, Doyle S3, Nafees B1

 

1UBC, London, UK, 2Ethicon, Livingston, UK, 3United BioSource Corporation, London, London, UK

   

 


9th Annual European Congress Main Pagee

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.
 
Website design by Eagle Systems USA, Inc.